来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置首页>技术资料首页>行业动态>行业动态>全球分子诊断市场在2017年价值81亿美元

全球分子诊断市场在2017年价值81亿美元

互联网2012年11月1日 8:30 点击:1409

新的市场研究报告,全球分子诊断市场,包括PCR、DNA测序、微阵列、光谱学技术,以及病毒学/传染性疾病、癌症/肿瘤学、基因测试应用程序,预测到2017年将达到81亿美元。

Global Molecular Diagnostics Market worth $8.1 Billion by 2017


 

The new market research report Molecular Diagnostics Market - Technologies (PCR, DNA Sequencing, Microarray, Spectroscopy), Applications (Virology/Infectious Diseases, Cancer/Oncology, Genetic Testing) - Global Opportunities, Competitor Analysis & Forecasts to 2017” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.

 

 

Browse 130+ market data tables/ figures spread through 391 pages and in-depth TOC of “Molecular Diagnostics Market - Technologies, Applications - Global Opportunities, Competitor Analysis & Forecasts to 2017”.
http://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html
Early buyers will receive 10% customization on reports.

This report studies the global molecular diagnostics market, with forecast to 2017.

Molecular diagnostics (MDx) is a new class of diagnostic tests that identify nucleic acids or proteins to test the status of a disease. These nucleic acids or proteins, which belong to individual patients or foreign organisms, help determine a specific therapy, or risk of developing a specific disease, or other health conditions. MDx is the fastest growing segment within the in-vitro diagnostic (IVD) space, driven by accuracy, high sensitivity, fast turnaround time, easy workflow, and cost-effective testing. Owing to these factors, the molecular diagnostics market crossed $4.8 billion in 2011, and is poised to grow at a CAGR of 9.1% in the next five years to reach $8.1 billion.

Molecular diagnostics has applications in infectious disease molecular testing, oncology, blood screening, genetic testing, DNA fingerprinting (e.g., paternity testing, forensic testing), microbiology, tissue typing, and food pathogen detection testing. The booming MDx areas are molecular tests for women’s health, oncology, and organ transplant testing.

Factors like increase in awareness and acceptance of personalized medicine, advancements in molecular techniques, and increasing investments in proteomics and genomics research will spur the molecular diagnostics market in the future. Yet, reimbursement issues for non-coded tests and complex regulatory framework will restrict the growth of this market.

Although the market for molecular diagnostics is fragmented with more than 500 companies, the most prominent players are Roche Diagnostics (Switzerland), Novartis (Switzerland), Gen-Probe (U.S.), Qiagen (The Netherlands), Abbott Diagnostics (U.S.), Becton Dickinson (U.S.) and Cepheid (U.S.), to name a few.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website www.marketsandmarkets.com

(来源: 互联网 )


全年征稿 / 资讯合作

联系邮箱:kefu@labbase.net

版权与免责声明

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.labbase.net,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。